These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38249187)

  • 1. A Straining Heart: Transthyretin Amyloidosis as a Cause of Heart Failure.
    Tender-Vieira J; Pinto C; Matias P; Marques P; Almeida JS
    Cureus; 2023 Dec; 15(12):e50957. PubMed ID: 38249187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
    Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
    Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac amyloidosis: An underdiagnosed/underappreciated disease.
    Manolis AS; Manolis AA; Manolis TA; Melita H
    Eur J Intern Med; 2019 Sep; 67():1-13. PubMed ID: 31375251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
    Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
    J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
    Klaassen SH; van Veldhuisen DJ; Nienhuis H; van den Berg MP; Hazenberg BP; van der Meer P
    Card Fail Rev; 2020 Mar; 6():e21. PubMed ID: 32944291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy.
    Bennani Smires Y; Victor G; Ribes D; Berry M; Cognet T; Méjean S; Huart A; Roussel M; Petermann A; Roncalli J; Carrié D; Rousseau H; Berry I; Chauveau D; Galinier M; Lairez O
    Int J Cardiovasc Imaging; 2016 Sep; 32(9):1403-1413. PubMed ID: 27240600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wild type transthyretin cardiac amiloidozis as a rare and overlooked underlying etiology in a patient with heart failure with preserved ejection fraction and left ventricular hypertrophy.
    Murat S; Çavuşoğlu Y; Ak Sivrikoz İ
    Turk Kardiyol Dern Ars; 2021 Oct; 49(7):579-584. PubMed ID: 34623301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transthyretin Cardiac Amyloidosis: An Evolution in Diagnosis and Management of an "Old" Disease.
    Smiley DA; Rodriguez CM; Maurer MS
    Cardiol Clin; 2022 Nov; 40(4):541-558. PubMed ID: 36210137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transthyretin cardiac amyloidosis: an under-diagnosed cause of heart failure.
    Molina O G; Judge D; Campbell W; Chahal H; Mugmon M
    J Community Hosp Intern Med Perspect; 2014; 4(5):25500. PubMed ID: 25432650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies.
    Halatchev IG; Zheng J; Ou J
    J Thorac Dis; 2018 Mar; 10(3):2034-2045. PubMed ID: 29707360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction.
    Chen W; Ton VK; Dilsizian V
    Curr Cardiol Rep; 2018 Mar; 20(4):23. PubMed ID: 29520480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy.
    Devesa A; Camblor Blasco A; Pello Lázaro AM; Askari E; Lapeña G; Gómez Talavera S; Taibo Urquía M; Rodríguez Olleros C; Tuñón J; Ibáñez B; Aceña Á
    ESC Heart Fail; 2021 Aug; 8(4):2856-2865. PubMed ID: 33963812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Senile Systemic Amyloidosis: An Underdiagnosed Disease.
    Manso MC; Marques DP; Rocha SL; Rodeia SC; Domingos R
    Eur J Case Rep Intern Med; 2017; 4(9):000725. PubMed ID: 30755970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac amyloidosis: updates in diagnosis and management.
    Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
    Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis.
    Hahn VS; Yanek LR; Vaishnav J; Ying W; Vaidya D; Lee YZJ; Riley SJ; Subramanya V; Brown EE; Hopkins CD; Ononogbu S; Perzel Mandell K; Halushka MK; Steenbergen C; Rosenberg AZ; Tedford RJ; Judge DP; Shah SJ; Russell SD; Kass DA; Sharma K
    JACC Heart Fail; 2020 Sep; 8(9):712-724. PubMed ID: 32653448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction.
    Ton VK; Mukherjee M; Judge DP
    Clin Med Insights Cardiol; 2014; 8(Suppl 1):39-44. PubMed ID: 25628512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of clinical characteristics of cardiac amyloidosis as a potential underlying etiology in patients diagnosed with heart failure with preserved ejection fraction.
    Murat S; Cavusoglu Y; Yalvac HE; Sivrikoz IA; Kocagil S
    Kardiol Pol; 2022; 80(6):672-678. PubMed ID: 35390167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction.
    Magdi M; Mostafa MR; Abusnina W; Al-Abdouh A; Doss R; Mohamed S; Ekpo CP; Alweis R; Baibhav B
    Am J Cardiovasc Dis; 2022; 12(3):102-111. PubMed ID: 35873185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of the HFA-PEFF and H
    Tomasoni D; Aimo A; Merlo M; Nardi M; Adamo M; Bellicini MG; Cani D; Franzini M; Khalil A; Pancaldi E; Panichella G; Porcari A; Rossi M; Vergaro G; Lombardi CM; Sinagra G; Rapezzi C; Emdin M; Metra M
    Eur J Heart Fail; 2022 Dec; 24(12):2374-2386. PubMed ID: 35855616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.